PlainPharmaWatch

CMS Open Payments · Program Year 2024

Napo Pharmaceuticals Inc

Napo Pharmaceuticals Inc reported $704,817.67 in payments to 1,430 physicians and teaching hospitals across 1,508 transactions.

See the rankings → How this is sourced
$704.8K
Total payments
1,508
Transactions
1,430
Recipients
−$9.8K
General Payments vs PY2023

Napo Pharmaceuticals Inc reported $704,817.67 in payments to 1,430 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #691 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $492.88 per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Napo Pharmaceuticals Inc pairs above-median payment volume with a broadly spread payment pattern across many recipients.

#691
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
3
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Napo Pharmaceuticals Inc's CMS-reported General Payments decreased by $9.8K (−4.9%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: NAPO PHARMACEUTICALS INCPY2023: NAPO PHARMACEUTICALS INCPY2024: Napo Pharmaceuticals Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$199.4KPY2024$189.6K
PY2023
$199,443.20
PY2024
$189,647.62

How Napo Pharmaceuticals Inc ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Napo Pharmaceuticals Inc's total vs. every reporting company

CMS Open Payments, Program Year 2024

$704,818 Top 36% higher than 64% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). This entry sits in this band. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Napo Pharmaceuticals Inc

Averaging $467.39 per transaction and $492.88 per recipient, Napo Pharmaceuticals Inc's Program Year 2024 total comes to $704,817.67 across 1,508 transactions and 1,430 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #691 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $93.7K across 31 transactions, 13.3% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Napo Pharmaceuticals Inc made 3 types of general payments. "Consulting Fee" is the largest category at $93.7K, 13.3% of the company's reported total.

How Napo Pharmaceuticals Inc divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$93.7K2. Compensation for Faculty …$62.2K3. Food and Beverage$33.8K
Payment Type Amount Transactions
Consulting Fee $93.7K 31
Compensation for Faculty or Speaker (Medical Education) $62.2K 22
Food and Beverage $33.8K 1,377

Recipient Concentration in General Payments

The five largest recipient relationships account for $86,469.73 (45.6%) of $189,647.62 in this company's General Payments records across 603 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Napo Pharmaceuticals Inc

The five named recipients with the highest reported General Payments from this company

Elie Schochet$23.0KRobin Hardwicke$21.8KSandra Swain$16.1KPablo Okhuysen$13.5KLee Schwartzberg$12.1K
  1. 1

    Elie Schochet

    $23,017.49 across 8 reported transactions

  2. 2

    Robin Hardwicke

    $21,843.73 across 19 reported transactions

  3. 3

    Sandra Swain

    $16,077.10 across 5 reported transactions

  4. 4

    Pablo Okhuysen

    $13,454.31 across 2 reported transactions

  5. 5

    Lee Schwartzberg

    $12,077.10 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $467.39. Average per recipient: $492.88.

Total Amount

$704,817.67

Avg per Transaction

$467.39

Avg per Recipient

$492.88

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Napo Pharmaceuticals Inc Share

0.0%

#691 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Napo Pharmaceuticals Inc

SurGenTec

$704.8K 249 recipients

Calvary Spine, LLC

$703.2K 0 recipients

Day One Biopharmaceuticals

$703.0K 191 recipients

Kuros Biosciences USA, Inc

$711.3K 1,447 recipients

Scilex Pharmaceuticals Inc.

$715.7K 19,348 recipients

ZOLL Respicardia, Inc.

$718.3K 1,630 recipients

Frequently Asked Questions

How much did Napo Pharmaceuticals Inc pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $704,817.67 from Napo Pharmaceuticals Inc to physicians and hospitals across 1,508 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Napo Pharmaceuticals Inc? ▾
1,430 physicians and teaching hospitals received payments from Napo Pharmaceuticals Inc in 2024, averaging $492.88 per recipient.
What types of payments did Napo Pharmaceuticals Inc make? ▾
3 categories of general payment make up Napo Pharmaceuticals Inc's reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Consulting Fee" at $93.7K, representing 13.3% of the company's reported total.
How does Napo Pharmaceuticals Inc rank among pharmaceutical companies? ▾
By total payment amount, Napo Pharmaceuticals Inc sits at #691 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Napo Pharmaceuticals Inc? ▾
In 2024, Napo Pharmaceuticals Inc averaged $467.39 per transaction across 1,508 transactions to 1,430 recipients.
Where does the payment data for Napo Pharmaceuticals Inc come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Napo Pharmaceuticals Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.